Product
CD30.CAR-T
2 clinical trials
10 indications
Indication
Hodgkin lymphomaIndication
AdultIndication
Hodgkin Lymphoma RecurrentIndication
Hodgkin lymphoma refractoryIndication
PediatricIndication
Anaplastic Large Cell LymphomaIndication
Peripheral T Cell LymphomaIndication
Extranodal NK/T-cell LymphomaIndication
Diffuse Large B-Cell LymphomaClinical trial
A Phase 2 Multi-Center Study Evaluating the Safety and Efficacy of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) in Adult and Pediatric Patients With Relapsed or Refractory Classical Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2022-11-22